Comprehensive Study Guide for Transfusion Medicine and DAT

Principle of the Antiglobulin Test (DAT)

1. Basic Principles

• IgM Antibodies: These antibodies are large enough to readily cause visible agglutination on their own during testing.
• IgG Antibodies: These antibodies do NOT cause visible agglutination by themselves because they are smaller and cannot bridge the distance between red blood cells (RBCs).

2. Detecting IgG (Anti-Human Globulin)

• To detect IgG, an Anti-Human Globulin (AHG) reagent is added.
• AHG binds specifically to the Fc portion of the IgG molecule.
• Common names for AHG:
      * Coomb’s antibody
      * Coomb’s serum
      * Refereed to colloquially as "The green stuff"

3. The Testing Process

• After adding AHG and centrifuging, the AHG reagent forms a physical bridge between IgG-coated red blood cells.
• This bridge creates visible agglutination, confirming the presence of the antibody.

Usage of Antiglobulin Testing

1. Antibody Screening and Identification

• Used to detect antibodies against non-ABO antigens.
• If results are positive, further testing is required before a transfusion can proceed.

2. Antigen Typing

• Determines if donor RBCs possess specific antigens.
• Essential for selecting compatible blood units for patients with known antibodies.

3. Direct Antiglobulin Testing (DAT)

• Standardly detects the in vivo coating of RBCs.
• Clinical suspects for DAT:
      * HDFN: Hemolytic Disease of the Fetus and Newborn.
      * AIHA: Autoimmune Hemolytic Anemia.
      * HTR: Hemolytic Transfusion Reaction.

Comparison of DAT vs. IAT

1. Direct Antiglobulin Test (DAT)

• Detection: Detects RBCs coated in vivo.
• Specimen: Uses patient RBCs.
• Purpose: Determines if the patient's RBCs are already coated with IgG or complement within their own body.

2. Indirect Antiglobulin Test (IAT)

• Detection: Detects antibodies in the serum.
• Specimen: Uses patient serum mixed with reagent RBCs.
• Purpose: Identifies unexpected antibodies or determines the presence of specific antigens.
• Key Distinction: DAT measures in vivo coating, while IAT measures an in vitro reaction.

DAT Details and Technical Specifications

1. What DAT Detects

• IgG coating.
• Complement components (specifically $C3b$ and $C3d$).
• A combination of both IgG and complement.
• Note: DAT does NOT detect IgM (unless it has activated complement) or IgA.

2. DAT Control

• The control consists of patient RBCs mixed with saline.
• A positive control result suggests polyagglutination.

3. Specimen Requirements

• A lavender top tube (EDTA) is required.
• EDTA functions by chelating Calcium ($Ca^{++}$) and Magnesium ($Mg^{++}$).
• This chelation prevents in vitro complement activation, ensuring that any complement detected by the test actually occurred in vivo.

DAT Procedure and Interpretation

1. Procedural Steps

• Start the test using polyspecific AHG reagent.
• If the initial result is positive, the test must be repeated using monospecific reagents.
• A fresh cell suspension must be prepared for the test.
• Requirement for Negative C3 Tests: If the complement (C3) test is negative, complement-coated "check cells" must be added to validate the negative result.

2. Interpretation of Positive Results

• A positive DAT indicates that RBCs are coated with antibody and/or complement.
• Associated Conditions:
      * HDFN: Maternal antibodies coat fetal RBCs.
      * HTR: Recipient antibodies coat donor RBCs.
      * AIHA: Autoantibodies coat the patient's own RBCs. Types include:
          * Warm AIHA.
          * Cold AIHA.
          * Paroxysmal Cold Hemoglobinuria (PCH).
      * Drug-induced hemolysis.

3. Follow-Up to a Positive DAT

• Clinical Evaluation: Review the patient's diagnosis, medications, and recent transfusion history.
• Laboratory Evaluation: Monitor Hematocrit ($Hct$), Hemoglobin ($Hb$), Bilirubin, and Lactate Dehydrogenase ($LDH$).

Elution: Theory and Practice

1. Definition and Mechanism

• Elution is the process of physically removing antibodies that are coated onto RBCs.
• It works by breaking the antigen-antibody bond, releasing the antibody into a liquid solution known as the eluate.

2. Purpose

• To identify the specific specificity of the antibody causing the reaction.
• The resulting eluate is tested against standard reagent RBC panels for identification.

Hemolytic Disease of the Fetus and Newborn (HDFN)

1. Definition and Pathophysiology

• HDFN involves a shortened lifespan for fetal or newborn RBCs caused by maternal IgG antibodies binding to fetal RBC antigens.
• Mechanism: Maternal IgG crosses the placenta and binds to fetal antigens. These coated RBCs are then destroyed by macrophages in the fetal spleen and liver via extravascular hemolysis.

2. Effects on the Fetus

• Anemia: Low RBC count due to destruction.
• Bone Marrow Response: Increased RBC production, leading to the release of nucleated red blood cells (NRBCs).
• Physiological Changes: Extramedullary hematopoiesis, hepatosplenomegaly, and cardiac failure.
• Advanced Complications: Hypoproteinemia and Hydrops fetalis (severe edema).

3. Effects After Birth

• Bilirubinemia: Accumulation of unconjugated bilirubin because the neonate's liver is immature.
• Jaundice: Yellowing of the skin/eyes.
• Kernicterus: Brain toxicity resulting from high bilirubin levels.

4. Requirements for HDFN Occurrence

1. The mother must be exposed to a foreign antigen (via transfusion or prior pregnancy).
2. The mother must produce an antibody against that antigen.
3. The antibody must be classes IgG (to cross the placenta).
4. The fetus must possess the corresponding antigen.

5. Sources of Exposure (Transplacental Hemorrhage)

• Before delivery: Abortion, ectopic pregnancy, amniocentesis, or chorionic villus sampling (CVS).
• At delivery: C-section, manual placenta removal, or prolonged delivery.
• Other: Trauma or transfusion.

Antibodies and Testing in HDFN

1. Antibodies Involved

• Most Severe: Anti-D (Rh system).
• Most Common:
      * Rh system: $D$, $E$, $c$.
      * Kell system antibodies.
      * ABO system antibodies.
• Less Common: Kidd, Duffy, and Ss (rare).

2. Maternal Testing Protocol

• Initial Visit: ABO, Rh, and antibody screen.
• If Rh Negative: Repeat the antibody screen at $28$ weeks.
• If Antibody Present: Perform antibody identification and titers; monitor every $2 ext{--}4$ weeks.

3. Paternal and Amniotic Testing

• Paternal Testing: Determines risk based on zygosity.
      * Homozygous: 100 ext{%} chance the baby has the antigen.
      * Heterozygous: 50 ext{%} chance the baby has the antigen.
• Amniotic Testing: Detects fetal antigens, blood type, and bilirubin levels (to gauge hemolysis severity).
• Cordocentesis (PUBS): Percutaneous Umbilical Blood Sampling to determine Hb, Hct, blood type, phenotype, and DAT.

4. Newborn Testing and Morphology

• Tests include Bilirubin, DAT, ABO/Rh typing, and CBC with H&H.
• RBC Morphology findings: NRBCs, Polychromasia, and Spherocytes.

ABO vs. Non-ABO HDFN

1. ABO HDFN

• Affects approximately 15 ext{%} of pregnancies at risk.
• Usually occurs in Type O mothers with an A or B baby.
• Characteristics: Mild severity; can occur in the first pregnancy; appears $12 ext{--}48$ hours post-birth.
• Treatment: Phototherapy.

2. Non-ABO HDFN (e.g., Rh)

• More severe; usually does not occur in the first pregnancy as it requires prior sensitization.
• Affects all future antigen-positive pregnancies once sensitized.

Rh Immune Globulin (RhIg)

1. Mechanism of Action

• RhIg is injectable Anti-D IgG.
• It binds to fetal $D+$ cells in maternal circulation so macrophages can remove them before the mother's immune system can respond.
• This prevents the formation of maternal Anti-D.

2. RhIg Dosage

• Full Dose ($300 ext{ }\mu\text{g}$): Covers $15 ext{ mL}$ of packed RBCs or $30 ext{ mL}$ of whole blood.
• Microdose ($50 ext{ }\mu\text{g}$): Covers $2.5 ext{ mL}$ of packed RBCs.

3. Administration Guidelines

• When to give: At $26 ext{--}28$ weeks gestation; within $72$ hours of delivery; after amniocentesis, PUBS, abortion, or trauma.
• When NOT to give: If the mother is Rh positive, if the mother has already developed Anti-D, or if the baby is Rh negative.
• Note: Passive Anti-D from RhIg can cause a positive maternal antibody screen for up to $3$ months.

Testing for Fetomaternal Hemorrhage (FMH)

1. Rosette Test (Screening)

• Detects $D+$ fetal cells in maternal blood.
• Positive: $\ge 3$ rosettes per $5$ low-power fields.
• Negative: < 3 rosettes per $5$ low-power fields.

2. Kleihauer-Betke (KB) Test (Quantitative)

• Based on fetal cells containing HbF, which is resistant to acid.
• Fetal cells appear bright pink; maternal cells appear ghost-like.

3. Calculations for RhIg Dosing

• $\text{Volume of FMH (mL)} = \% \text{ fetal cells} \times 50$
• $\text{Number of RhIg vials} = \frac{\text{FMH}}{30}$
• Rule: Always add $1$ additional vial to the calculated result.

Clinical Treatments for HDFN

• Phototherapy: Uses UV light ("bili light") to break down bilirubin.
• Intrauterine Transfusion: Performed via the umbilical vein to treat fetal anemia; goal is to maintain Hb > 10\text{ g/dL}.
• Exchange Transfusion: Post-birth procedure that removes bilirubin and maternal antibodies while replacing coated RBCs with donor blood.

Blood Donation Process

1. Market Statistics (U.S.)

• Donation needed every $2$ seconds.
• $41,000+$ donations are required daily; $30 ext{ million}$ components transfused annually.
• Less than 10 ext{%} of eligible people donate.
• Type O-negative: Universal RBC donor; high demand.
• AB Plasma: Universal plasma donor.

2. Types of Donations

• Allogeneic: Donated for general use by others.
• Autologous: Donated for self-use. Minimum $Hct$ of 33 ext{%}. Can donate every $3$ days ($7$ days recommended).
• Directed: For a specific person. Must be irradiated if from a skeletal relative to prevent GVHD. Husbands/Mothers are discouraged from donating to wives/children due to HDFN/Sensitization risks.

3. Donation Frequency Limits

• Whole Blood (RBCs): Every $56$ days.
• Double RBCs: Every $112$ days.
• Platelets: Every $7$ days (maximum $24$ times per year).

Donor Eligibility and Phlebotomy

1. General Physical Requirements

• Age: Minimum $17$ years ($16$ with consent in Arkansas).
• Weight: Minimum $110\text{ lbs}$.
• Hemoglobin ($Hb$): Minimum $12.5\text{ g/dL}$ (low Hb is the most common reason for deferral).

2. The 4-Step Donation Process

• Step 1: Registration (ID check and eligibility review).
• Step 2: Health History & Mini-Physical (Temp, pulse, BP, Hb check).
• Step 3: Phlebotomy (The actual donation).
      * Amount collected: approx. $1\text{ pint}$.
      * Duration: $8\text{--}10$ minutes for the draw ($1\text{ hour } 15\text{ minutes}$ total visit).
      * Diversion: The first $30\text{--}40\text{ mL}$ of blood is diverted to reduce contamination risk.
• Step 4: Refreshments (Rest for $10\text{--}15$ minutes).

Special Donation and Testing

1. Double Red Cell Donation Reqs

• Males: Height $\ge 5'1"$, Weight $\ge 130\text{ lbs}$.
• Females: Height $\ge 5'5"$, Weight $\ge 150\text{ lbs}$.

2. Intra-Operative Autologous Collection ("Cell Saver")

• Blood collected during surgery; must be reinfused within $24$ hours.

3. Mandatory Lab Testing

• HIV 1 & 2, Hepatitis B & C, Syphilis, HTLV-I/II, West Nile Virus, Trypanosoma cruzi (Chagas), Babesia, CMV, and COVID.

Blood Component Preparation

1. Collection and System

• Uses a 4-bag system producing approx. $500\text{ cc}$ of whole blood.
• Contains $70\text{ mL}$ of CPD (Citrate, Phosphate, Dextrose).
      * Citrate: Anticoagulant.
      * Phosphate: Buffer/ATP support.
      * Dextrose: Nutrient.

2. Separation Process

• Soft Spin (Primary): Separates RBCs from Platelet-rich plasma (PRP).
• Hard Spin (Secondary): Separates PRP into Platelets and Plasma.

3. Red Blood Cell Products

• CPD RBCs: Volume $200 ext{--}250\text{ mL}$; $Hct$ 75 ext{--}85 ext{%}; Expiration $21$ days.
• Additive Solution (AS) RBCs: Volume $300 ext{--}350\text{ mL}$; $Hct$ 55 ext{--}60 ext{%}; Expiration $42$ days.
      * AS Components: Adenine (ATP), Saline/Dextrose, Mannitol (membrane stability), Citrate.
• Clinical Impact: $1\text{ unit}$ RBCs increases $Hct$ by approximately 3 ext{%}. Used for blood loss > 25 ext{%} or anemia (Hct < 26 ext{%}).

The "Storage Lesion" and RBC Health

1. Biochemical Changes during Storage

• Decreases: Glucose, pH, ATP, $2,3 ext{-}DPG$, Sodium.
• Increases: Potassium ($K^+$), Hemolysis.
• Note: ATP is the main factor in RBC effectiveness; $2,3 ext{-}DPG$ levels are restored $24$ hours after transfusion.

2. Specialized RBC Products

• Fresh RBCs: < 5 days old; used for neonates and pediatrics.
• Leukoreduced: WBCs removed via filtration to reduce cytokines and CMV risk.
• Irradiated RBCs: Exposed to $25\text{ Gy}$ radiation to prevent T-cell proliferation and Graft-versus-Host Disease (GVHD).

Platelets, Plasma, and Cryoprecipitate

1. Platelets

• Stored at $20 ext{--}24\text{ }^\circ\text{C}$ with constant agitation.
• Random Donor Platelets (RDP): Pooled in groups of $4 ext{--}6$; increases count by $25,000 ext{--}50,000$.
• Apheresis Platelets: From one donor; equivalent to $4 ext{--}5$ RDP units; reduces alloimmunization risk.
• Risk: Bacterial contamination (approx. 0.1 ext{--}0.2 ext{%}); detected via culture or PCR.

2. Plasma Products

• FFP: Frozen within $8$ hours; contains all factors. Stored at $-18\text{ }^\circ\text{C}$ for $1\text{ year}$.
• 24-Hour Plasma: Frozen within $24$ hours; slight decrease in Factors V and VIII.
• Thawed Plasma: Good for $5$ days; deficient in Factors V and VIII.

3. Cryoprecipitate (Frozen Factor-Rich Concentrate)

• Contents: Factor VIII ($\ge 80\text{ IU}$), Fibrinogen ($\ge 150\text{ mg}$), vWF, Factor XIII.
• Prep: Made from FFP; thawed at $4\text{ }^\circ\text{C}$ and refrozen.
• Storage: Thawed at $20 ext{--}24\text{ }^\circ\text{C}$. Valid for $6$ hours ($4$ hours if pooled in lab).

Transfusion Reactions

1. Acute Hemolytic Transfusion Reaction (AHTR)

• Cause: Usually ABO incompatibility (human error).
• Pathophysiology: Intravascular hemolysis via complement activation.
• Symptoms: Fever, back/flank pain, hypotension, "feeling of doom."
• Trivia: Can occur with as little as $10\text{ mL}$ of blood.

2. Delayed Hemolytic Transfusion Reaction (DHTR)

• Cause: Secondary immune response (anamnestic) to non-ABO antigens.
• Onset: $Days ext{--}weeks$.
• Clinical: Fever, anemia, jaundice, lack of hematocrit rise.

3. Other Reactions

• Allergic: IgE-mediated response to plasma proteins; treat with Benadryl.
• Anaphylactic: Often seen in IgA-deficient patients with anti-IgA; requires washed RBCs.
• FNHTR: Temperature rise > 1\text{ }^\circ\text{C}; caused by WBC antibodies/cytokines.
• TRALI: Donor antibodies damage recipient lung capillaries; pulmonary edema within $1 ext{--}2$ hours.
• TACO: Fluid overload (non-immune); seen in elderly/cardiac patients; treat with diuretics.
• GVHD: Donor T-cells attack host; mortality > 90 ext{%}; prevented by irradiation.

Laboratory Work-up for Reactions

1. Basic Work-up (Mandatory)

• Clerical check (identification errors).
• Visual hemolysis check (Pink/Red = Acute, Yellow = Delayed).
• DAT (look for mixed-field reactions).
• Repeat ABO typing.

2. Extended Work-up (If DAT positive)

• Perform elution.
• Repeat antibody screen and crossmatch.
• Test for hemolysis markers: decreased haptoglobin, increased Bilirubin, increased LDH.

Quality and Regulations in Transfusion Medicine

1. FDA’s Five Layers of Safety

1. Donor Screening: Identify risk factors.
2. Testing: For infectious diseases and compatibility.
3. Deferred Donor Lists: Prevent unsafe donations.
4. Quarantine: Hold blood until testing is complete.
5. Reporting: Mandatory reporting of errors and fatalities to CBER.

2. Regulatory Bodies and Standards

• CBER: Center for Biologics Evaluation and Research.
• cGMP: Current Good Manufacturing Practices.
• Inspections: Every $2\text{ years}$ for blood centers/banks.

3. 12 Quality System Essentials (QSEs)

• Organization, Customer Focus, Personnel, Equipment, Purchasing/Inventory, Process Management (the most comprehensive), Documents/Records (Principle: If not documented, it wasn't done), Information Management, Nonconformance, Assessments, Continual Improvement (PDCA Cycle), Facilities/Safety.

4. Quality Concepts

• Quality Control (QC): Detects failures in routine operations.
• Quality Assurance (QA): Planned actions to ensure systems function.
• Quality Systems (QS): The framework integrating QC and QA.
• Note: Compliance is a "snapshot in time" (periodic), whereas Quality Management is continuous and proactive.